1. Home
  2. QNRX vs DRCT Comparison

QNRX vs DRCT Comparison

Compare QNRX & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quoin Pharmaceuticals Ltd.

QNRX

Quoin Pharmaceuticals Ltd.

HOLD

Current Price

$7.45

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Logo Direct Digital Holdings Inc.

DRCT

Direct Digital Holdings Inc.

HOLD

Current Price

$1.68

Market Cap

8.9M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
QNRX
DRCT
Founded
2018
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
10.1M
8.9M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
QNRX
DRCT
Price
$7.45
$1.68
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$330.00
AVG Volume (30 Days)
34.7K
7.3M
Earning Date
03-12-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$35,369,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$25.40
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.01
$1.51
52 Week High
$41.80
$80.30

Technical Indicators

Market Signals
Indicator
QNRX
DRCT
Relative Strength Index (RSI) 33.58 48.37
Support Level $7.07 $1.80
Resistance Level $8.46 $6.04
Average True Range (ATR) 0.88 0.68
MACD -0.13 -0.17
Stochastic Oscillator 19.75 1.74

Price Performance

Historical Comparison
QNRX
DRCT

About QNRX Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

About DRCT Direct Digital Holdings Inc.

Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.

Share on Social Networks: